Pseudomonas Aeruginosa Infections Among COVID-19 Patients in Intensive Care Units at CHRU of Nancy (Pyo-COVID-3)
Study Details
Study Description
Brief Summary
- aeruginosa is an opportunistic bacterium known to be responsible for numerous healthcare-associated infections, particularly in intensive care units (ICU). The frequency of these infections seems to have increased during the first waves of the COVID-19 pandemic. Identifying cases of co-infection and secondary infections with P. aeruginosa in patients with COVID-19 would provide a better understanding of the epidemiological evolution and characteristics of infected patients.
Treatment of P. aeruginosa infections requires the use of antibiotics. Antibiotic resistance is a growing problem, with an increase in resistance among P. aeruginosa strains. The misuse of antibiotics to treat patients can accentuate the phenomenon of antibiotic resistance, and failure to take account of resistance revealed by antibiograms can compromise patient recovery. Analysis of bacteriological results and patient medical records would enable a posteriori evaluation of the proper use of antibiotics (choice and adaptation of molecules, doses and duration of prescriptions), and identify any areas for improvement.
The main objective is to describe the evolution of P. aeruginosa infections in ICU patients with COVID-19 during the first 3 waves of COVID-19 (01/03/2020 to 31/05/2021). Secondary objectives are to describe the typology of P. aeruginosa strains identified among included patients (sampling sites and resistance profiles), to assess antibiotic prescriptions for these patients and to describe the relapse rate of included patients with a first P. aeruginosa infection.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Included Patient hospitalized between 01/03/20 and 31/05/21 in an intensive care unit of the Nancy University Hospital for at less 48 h for COVID-19 acute respiratory distress syndrome and presenting a positive sample for P. aeruginosa during his stay in the intensive care unit. |
Other: Observation
No intervention: observational study
|
Outcome Measures
Primary Outcome Measures
- P. aeruginosa occurence [From 01 March 2020 to 31 May 2021.]
The occurrence of Pseudomonas aeruginosa infection during the ICU stay of a COVID-19 patient.
Secondary Outcome Measures
- P. aeruginosa sample [From 01 March 2020 to 31 May 2021.]
Distribution of different types of samples (respiratory, blood, urine, etc.) positive for P. aeruginosa.
- P. aeruginosa resistance [From 01 March 2020 to 31 May 2021.]
The proportion of resistance to the various antibiotics tested on the P. aeruginosa strains identified.
- P. aeruginosa antibiotic treatment [From 01 March 2020 to 31 May 2021.]
Compliance of antibiotic prescriptions with reference recommendations is assessed by comparing data from patients' medical records.
- P. aeruginosa recurrence [From 01 March 2020 to 31 May 2021.]
Occurrence of a new P. aeruginosa infection.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patient hospitalized between 01/03/20 and 31/05/21 in anintensive care unit at Nancy University Hospital,
-
Patient hospitalized for at less 48 h in an intensive care unit for COVID-19 acute respiratory distress syndrome,
-
Patient with a positive P. aeruginosa sample during his/her stay in the intensive care unit.
Exclusion Criteria:
- Patient under 18 at time of hospitalization.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Nancy University Hospital | Vandœuvre-lès-Nancy | Lorraine | France | 54500 |
Sponsors and Collaborators
- Central Hospital, Nancy, France
Investigators
- Principal Investigator: Arnaud Florentin, Dr, a.florentin@chru-nancy.fr
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2023PI186